Julia Elizabeth Clark

Julia Elizabeth Clark

Auto-generated profile, based on publicly available information

Julia Elizabeth Clark

Department of Infectious Diseases Queensland Children's Hospital Brisbane Queensland Australia

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2011 in Thorax
Verified
Journal Article
Open access
PDF file
MHMichael Harris
Michael Harris
JCJulia Clark
Julia Clark
NCNicky Coote
Nicky Coote
PFPenny Fletcher
Penny Fletcher
AHAnthony Harnden
Anthony Harnden
OCOn behalf of the British Thoracic Society Standards of Care Committee
On behalf of the British Thoracic Society Standards of Care Committee
The British Thoracic Society first published management guidelines for community acquired pneumonia in children in 2002 and covered available evidence to early 2000. These updated guidelines represent a review of new evidence since then and consensus clinical opinion where evidence was not found. This document incorporates material from the 2002 guidelines and supersedes the previous guideline document.

7 June 2010 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
ISI. Solovic
I. Solovic
MSMartina Sester
Martina Sester
JGJ.J. Gomez-Reino
J.J. Gomez-Reino
HRH.L. Rieder
H.L. Rieder
SES. Ehlers
S. Ehlers
CLChristoph Lange
Christoph Lange
Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. Individuals who are treated with TNF antagonists are at an increased risk of reactivating latent infections, especially tuberculosis (TB).Following TNF antagonist therapy, the relative risk for TB is increased up to 25 times, depending on the clinical setting and the TNF antagonist used. Interferon-γ release assays or, as an alternative in individuals without a history of bacille Calmette–Guérin vaccination, tuberculin skin testing is recommended to screen all adult candidates for TNF antagonist treatment for the presence of latent infection withMycobacterium tuberculosis.Moreover, paediatric practice suggests concomitant use of both the tuberculin skin test and an interferon-γ release assay, as there are insufficient data in children to recommend one test over the other. Consequently, targeted preventive chemotherapy is highly recommended for all individuals with persistentM. tuberculosis-specific immune responses undergoing TNF antagonist therapy as it significantly reduces the risk of progression to TB.This TBNET consensus statement summarises current knowledge and expert opinions and provides evidence-based recommendations to reduce the TB risk among candidates for TNF antagonist therapy.

1 August 2016 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
BMBrendan J McMullan
Brendan J McMullan
DADavid Andresen
David Andresen
CBChristopher Charles Blyth
Christopher Charles Blyth
MAMinyon L Avent
Minyon L Avent
Asha BowenAsha Bowen
Asha Bowen
PBPenelope A Bryant
Penelope A Bryant

1 June 2004 in Thorax
Verified
Journal Article
Open access
PDF file
KEK M Eastham
K M Eastham
RFR Freeman
R Freeman
AKA M Kearns
A M Kearns
GEG Eltringham
G Eltringham
JCJ Clark
J Clark
DSD A Spencer
D A Spencer
Background: The incidence of empyema in children in the UK is increasing. The reason for this is unclear. A prospective study was undertaken to investigate the clinical features, aetiology, and outcome of cases of empyema and parapneumonic effusion presenting to a tertiary paediatric respiratory centre between February 1997 and August 2001. Method: Routine bacterial culture of blood and pleural fluid was performed for 47 cases. Forty three pleural fluid specimens, culture negative for pneumococcus, were analysed for pneumococccal DNA by real time polymerase chain reaction (PCR). Penicillin susceptibility was determined for DNA positive specimens using complementary PCR assay. Capsular serotype specific antigen detection was by enzyme immunoassay (EIA) using monoclonal antibodies to serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Clinical data were obtained from patient notes, supplemented by a postal questionnaire. Results: The median (range) age of the patients was 5.6 (0.6–16.9) years and 70% were male. The median (range) duration of illness before referral to hospital was 5 (0–25) days. Forty five (96%) had received antibiotics before referral; 32 (68%) required decortication and eight (21%) thoracocentesis. Median postoperative stay was 4 days (2–8). Thirty two (75%) pneumococcal culture negative specimens were pneumococcal DNA positive; 17 (53%) of these were serotype 1. All were penicillin sensitive. Conclusions: Pneumococcus is the major pathogen in childhood empyema and serotype 1 is the prevalent serotype. This has implications for vaccine development and immunisation strategy as the current 7-valent pneumococcal conjugate vaccine does not protect against serotype 1.

8 December 2014 in Internal Medicine Journal
Verified
Journal Article
Open access
PDF file
SFS. Fleming
S. Fleming
CYC. K. Yannakou
C. K. Yannakou
GHG. M. Haeusler
G. M. Haeusler
JCJ. Clark
J. Clark
AGA. Grigg
A. Grigg
Monica SlavinMonica Slavin
Monica Slavin
There is a strong argument for the use of antifungal prophylaxis in high‐risk patients given the significant mortality associated with invasive fungal disease, the late identification of these infections, and the availability of safe and well‐tolerated prophylactic medications. Clinical decisions about which patients should receive prophylaxis and choice of antifungal agent should be guided by risk stratification, knowledge of local fungal epidemiology, the efficacy and tolerability profile of available agents, and estimates such as number needed to treat and number needed to harm. There have been substantial changes in practice since the 2008 guidelines were published. These include the availability of new medications and/or formulations, and a focus on refining and simplifying patient risk stratification. Used in context, these guidelines aim to assist clinicians in providing optimal preventive care to this vulnerable patient demographic.

1 August 2019 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PBPhilip N Britton
Philip N Britton
RDRussell C Dale
Russell C Dale
CBChristopher C Blyth
Christopher C Blyth
JCJulia E Clark
Julia E Clark
NCNigel Crawford
Nigel Crawford
CJCheryl A Jones
Cheryl A Jones
Background: We aimed to determine the contemporary causes, clinical features, and short-term outcome of encephalitis in Australian children. Methods: We prospectively identified children (≤14 years of age) admitted with suspected encephalitis at 5 major pediatric hospitals nationally between May 2013 and December 2016 using the Paediatric Active Enhanced Disease Surveillance (PAEDS) Network. A multidisciplinary expert panel reviewed cases and categorized them using published definitions. Confirmed encephalitis cases were categorized into etiologic subgroups. Results: From 526 cases of suspected encephalitis, 287 children met criteria for confirmed encephalitis: 57% (95% confidence interval [CI], 52%–63%) had infectious causes, 10% enterovirus, 10% parechovirus, 8% bacterial meningoencephalitis, 6% influenza, 6% herpes simplex virus (HSV), and 6% Mycoplasma pneumoniae; 25% (95% CI, 20%–30%) had immune-mediated encephalitis, 18% acute disseminated encephalomyelitis, and 6% anti-N-methyl-d-aspartate receptor encephalitis; and 17% (95% CI, 13%–21%) had an unknown cause. Infectious encephalitis occurred in younger children (median age, 1.7 years [interquartile range {IQR}, 0.1–6.9]) compared with immune-mediated encephalitis (median age, 7.6 years [IQR, 4.6–12.4]). Varicella zoster virus encephalitis was infrequent following high vaccination coverage since 2007. Thirteen children (5%) died: 11 with infectious causes (2 influenza; 2 human herpesvirus 6; 2 group B Streptococcus; 2 Streptococcus pneumoniae; 1 HSV; 1 parechovirus; 1 enterovirus) and 2 with no cause identified. Twenty-seven percent (95% CI, 21%–31%) of children showed moderate to severe neurological sequelae at discharge. Conclusions: Epidemic viral infections predominated as causes of childhood encephalitis in Australia. The leading causes include vaccine-preventable diseases. There were significant differences in age, clinical features, and outcome among leading causes. Mortality or short-term neurological morbidity occurred in one-third of cases.